Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, steady-state pharmacokinetics and pharmacodynamics of IMG-7289 (Bomedemstat) in myelofibrosis
2018-003811-23Phase 2Completed
- Sponsor
- Imago BioSciences, Inc.
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bomedemstat in myelofibrosis (MF) and post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by Imago BioSciences, Inc. Primary endpoints: Safety and tolerability of IMG-7289 (Bomedemstat), Steady-state pharmacokinetics of IMG-7289 and 1 more. Started Sep 2019; status: completed.
02
Drugs
bomedemstat
03
Conditions
myelofibrosis (MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on 2018-003811-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003811-23.